Therapeutic Areas
Cardiometabolic Diseases
Cardiometabolic diseases such as diabetes, obesity, and dyslipidemia are among the leading global causes of morbidity and mortality, with particularly high and rising prevalence across the MENA region. Many patients still face complex regimens, poor control, and high cardiovascular risk despite available therapies. At Tyriaq, we focus on value-enhanced medicines and meaningful fixed-dose combinations that simplify treatment, support adherence, and better align with real-world patient journeys in our region.
Gastroenterology
Digestive disorders including GERD, functional dyspepsia, motility problems, and acid-related disease affect hundreds of millions worldwide and are highly prevalent in MENA, driven by diet, lifestyle, and rising comorbidities such as obesity and diabetes. Many patients live with persistent symptoms, overuse of short-term remedies, or suboptimal long-term control. Tyriaq is developing patient-friendly formulations and value-enhanced therapies, including Manuka-based and combination approaches, to improve symptom control, tolerability, and day-to-day quality of life.
Urology
Conditions such as benign prostatic hyperplasia (BPH), erectile dysfunction, and lower urinary tract symptoms are widely underdiagnosed and undertreated globally and across MENA, often with significant impact on quality of life, mental health, and relationships. Patients frequently manage fragmented therapy for multiple overlapping conditions. Tyriaq is working on clinically meaningful combinations and optimized regimens that reflect real-world comorbidities, aiming to provide more convenient, better-tolerated options for patients and prescribers.
Pain Management
Pain whether acute, chronic, musculoskeletal, neuropathic, or cancer-related remains one of the most common reasons for seeking medical care worldwide, including across the MENA region. Patients often face a trade-off between efficacy, safety, and tolerability, and may receive fragmented or short-term treatment strategies. Tyriaq aims to contribute to smarter pain management through rational combinations, value-enhanced formulations, and patient centric dosing strategies designed to optimize relief while minimizing risk of side effects and complexity.
Hepatology
Chronic liver diseases including NAFLD/NASH, viral hepatitis, and metabolic-driven liver damage represent a growing global health challenge, with particularly high burden in MENA due to obesity, diabetes, and changing lifestyles. Many patients are diagnosed late, face limited pharmacological options, or struggle with long-term adherence. While still an emerging focus for Tyriaq, our strategy is to build stepwise capabilities in hepatology by leveraging cardiometabolic expertise, exploring supportive combinations, and preparing for future therapies that can be integrated into regional care pathways.